The Clinical Significance of Simultaneous IL-17A and IL-17F Blockade in Psoriasis Non-Responding to Anti-IL17A Therapy

The better understanding of the immunopathogenesis of psoriasis has led to the development of highly efficacious targeted therapies with favorable safety profiles. Among them, the class of Interleukin (IL)-17 antibodies are well established for the treatment of psoriasis, psoriatic arthritis and axi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kokolakis, Georgios, Ghoreschi, Kamran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820893/
https://www.ncbi.nlm.nih.gov/pubmed/36614836
http://dx.doi.org/10.3390/jcm12010035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820893/
https://www.ncbi.nlm.nih.gov/pubmed/36614836
http://dx.doi.org/10.3390/jcm12010035

Ejemplares similares